aranesp darbepoetin alfa (rch) 300 microgram/0.6ml injection syringe with automatic needle guard
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy
aranesp darbepoetin alfa (rch) 200 microgram/0.4ml injection syringe with automatic needle guard
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; sodium chloride; polysorbate 80; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy
aranesp darbepoetin alfa (rch) 150 microgram/0.3ml injection syringe with automatic needle guard
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; polysorbate 80; water for injections; sodium chloride - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy
aranesp darbepoetin alfa (rch) 300 microgram/0.6ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; polysorbate 80; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 200 microgram/0.4ml injection syringe
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 150 microgram/0.3ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 300 microgram/0.6ml injection syringe
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: water for injections; dibasic sodium phosphate; sodium chloride; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 200 microgram/0.4ml injection syringe
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy
aranesp darbepoetin alfa (rch) 150 microgram/0.3ml injection syringe
amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy
aranesp 500 mcg
amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 500 mcg/ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age.aranesp ® is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.